Citation Impact
Citing Papers
Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases
2011 Standout
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
2016 Standout
Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene
2004 StandoutNobel
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
2009
Hallmarks of Cancer: The Next Generation
2011 Standout
The relationship between prognostic and predictive factors in the management of breast cancer
1998
From stress to inflammation and major depressive disorder: A social signal transduction theory of depression.
2014 Standout
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
2014 Standout
Creating new fluorescent probes for cell biology
2002 StandoutNobel
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
2006 Standout
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
2004 Standout
Requirement for CDK4 kinase function in breast cancer
2006
The RB and p53 pathways in cancer
2002 Standout
Control of Cyclin D1 and Breast Tumorigenesis by the EglN2 Prolyl Hydroxylase
2009 StandoutNobel
Reactions in Droplets in Microfluidic Channels
2006 Standout
Chemotherapy for small cell lung cancer
2003
Human papillomavirus oncoproteins: pathways to transformation
2010 Standout
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
2007 Standout
Racial differences in the expression of cell cycle–regulatory proteins in breast carcinoma
2004
NF-κB in cancer: from innocent bystander to major culprit
2002 Standout
Cyclin-D1 expression in human renal-cell carcinoma
1999
Drug penetration in solid tumours
2006 Standout
Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer
1999
Health services for children in western Europe
2013
In utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical application
2016
Stress, depression, the immune system, and cancer
2004
Tailoring to RB: tumour suppressor status and therapeutic response
2008
Cyclin D1 and breast cancer
2006
Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma
2012
Expression of “Spot 14” (THRSP) predicts disease free survival in invasive breast cancer: immunohistochemical analysis of a new molecular marker
2006
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer
2003 Standout
Molecular markers in male breast carcinoma
1998
Depression as a predictor of disease progression and mortality in cancer patients
2009
Amniotic fluid stabilized lipid nanoparticles for in utero intra-amniotic mRNA delivery
2021 StandoutNobel
Tissue microarrays for high-throughput molecular profiling of tumor specimens
1998 Standout
Activation of cyclin D1 expression by the ERK5 cascade
2003
p21 in cancer: intricate networks and multiple activities
2009 Standout
Aptamers as targeted therapeutics: current potential and challenges
2016 Standout
Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
2005
Male breast cancer
2006 Standout
Signaling—2000 and Beyond
2000 Standout
Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.
1993 Standout
Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?
2007 Standout
Monitoring protein conformations and interactions by fluorescence resonance energy transfer between mutants of green fluorescent protein
2000 StandoutNobel
Specific protection against breast cancers by cyclin D1 ablation
2001 Nature
Recent advances in technology for measuring and manipulating cell signals
2000 StandoutNobel
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Subjective wellbeing, health, and ageing
2014 StandoutNobel
Stress-induced immune dysfunction: implications for health
2005 Standout
Microtubules as a target for anticancer drugs
2004 Standout
Cell cycle, CDKs and cancer: a changing paradigm
2009 Standout
Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1
1998
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
Cyclins and cdks in development and cancer: a perspective
2005
Expression of cyclins A and D and p21(waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival
1999
Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment
2002
Cyclin-d1-gene amplification and expression in breast carcinoma: Relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21waf1 immunohistochemical expression
1997
Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: an updated systematic analysis
2014 Standout
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
2006 Standout
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
Differential Control of Transcription by DNA-bound Cyclins
2001 StandoutNobel
Disparities in breast cancer outcomes between Caucasian and African American women: a model for describing the relationship of biological and nonbiological factors
2013
Social isolation, loneliness, and all-cause mortality in older men and women
2013 Standout
Genetically encoded reporters of protein kinase A activity reveal impact of substrate tethering
2001 StandoutNobel
Effect of the Selective Estrogen Receptor Modulator Arzoxifene on Repopulation of Hormone-Responsive Breast Cancer Xenografts between Courses of Chemotherapy
2005
Imaging Protein Kinase Cα Activation in Cells
1999 Science
Expression of cyclin A and D proteins in prostate cancer and their relation to clinopathological variables and patient survival
1999
Transcriptional regulation of the cyclin D1 gene at a glance
2008
ErbB2/Neu-Induced, Cyclin D1-Dependent Transformation Is Accelerated in p27-Haploinsufficient Mammary Epithelial Cells but Impaired in p27-Null Cells
2002
Ionizable lipid nanoparticles for in utero mRNA delivery
2021 StandoutNobel
Cancer treatment and survivorship statistics, 2016
2016 Standout
Long Noncoding RNAs: Past, Present, and Future
2013 Standout
Cyclin-Dependent Kinase 4 Expression Is Essential for Neu-Induced Breast Tumorigenesis
2005
Therapy of small cell lung cancer: a perspective on two decades of clinical research.
1988
Identification of the E2A Gene Products as Regulatory Targets of the G1 Cyclin-dependent Kinases
2001
On-Chip Titration of an Anticoagulant Argatroban and Determination of the Clotting Time within Whole Blood or Plasma Using a Plug-Based Microfluidic System
2006
Genetically encoded fluorescent reporters of protein tyrosine kinase activities in living cells
2001 StandoutNobel
Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations
2010 Standout
Emerging Droplet Microfluidics
2017 Standout
Guidelines for the management of hemophilia
2012 Standout
Breast Cancer in Men
2002 Standout
WFH Guidelines for the Management of Hemophilia, 3rd edition
2020 Standout
Works of Michael Richards being referenced
Diagnosing childhood cancer in primary care – a realistic expectation?
2004
Guideline on the management of haemophilia in the fetus and neonate*
2011
Point-of-care testing of neonatal coagulation
2006
Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations
2009
Cyclin D1 and prognosis in human breast cancer
1996
A survey of adherence to haemophilia therapy in six European countries: results and recommendations
2008
Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations
2011
Stressful life experiences and risk of relapse of breast cancer: observational cohort study
2002
Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: A randomised, controlled trial
1986